{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:01:22Z","timestamp":1793826082202,"version":"4.6.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gaucher disease (GD) is a rare lysosomal disorder of sphingolipid catabolism, characterised by a block in the degradation of glucosylceramide (GlcCer) to ceramide. The resulting effect is lysosomal accumulation of GlcCer and its deacylated derivative, glucosylsphingosine. Secondary alterations in the sphingolipid metabolic pathway have been reported, including elevated concentrations of ceramide, lactosylceramide (dihexosylceramide (DHC)), and gangliosides, however, there are notable inconsistencies across different cell and tissue types and their relevance to GD pathology is not well-understood. Sphingolipids are crucial for the regulation of intra- and extracellular functions and different cell types have different requirements. For example, neurons have a high demand for complex sphingolipids due to their extensive membrane remodelling networks necessary for their communication role. We therefore performed literature searches of PubMed, Scopus, and Web of Science databases to coalesce reports of sphingolipids in different animal and cell models of GD, as well as human cells and tissues from 1965 to 2024, totalling 54 studies. We found that DHC, trihexosylceramide, and simple gangliosides, G\n                    <jats:sub>M3<\/jats:sub>\n                    , G\n                    <jats:sub>M2<\/jats:sub>\n                    , G\n                    <jats:sub>M1<\/jats:sub>\n                    , G\n                    <jats:sub>D3<\/jats:sub>\n                    , and G\n                    <jats:sub>D2<\/jats:sub>\n                    , were elevated in most reports (79%), complex G\n                    <jats:sub>T<\/jats:sub>\n                    gangliosides were largely decreased (75%), and G\n                    <jats:sub>D1a<\/jats:sub>\n                    , G\n                    <jats:sub>D1b<\/jats:sub>\n                    , and G\n                    <jats:sub>Q1b<\/jats:sub>\n                    were inconsistently reported to be both increased and decreased in individual studies. Similarly, ceramide was highly discrepant between various cell and tissue types: spleen ceramide was elevated in two of three reports, brain ceramide was largely unchanged (82%), and ceramide concentrations in the skin were not consistent by any variable, including assay technique or GD sub-variant. Some of these discrepancies may be explained by biological variability and differences in methods used to measure sphingolipids, mass spectrometry being the most common, but it is clear that there are sphingolipid alterations in GD, which likely contribute to tissue-specific pathology. Evidence that sphingolipid metabolic regulation is variable across cells and tissues highlight the importance of characterising individual sphingolipid profiles on a model-to-model basis as a driving force behind cell pathology.\n                  <\/jats:p>","DOI":"10.1186\/s13023-025-04015-5","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:24:30Z","timestamp":1762417470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sphingolipids in Gaucher disease: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"given":"Ashleigh","family":"Lake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-8942","authenticated-orcid":false,"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"4015_CR1","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.3390\/ijms22115793","volume":"22","author":"BM Quinville","year":"2021","unstructured":"Quinville BM, Deschenes NM, Ryckman AE, Walia JS. A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis. Int J Mol Sci. 2021;22:5793.","journal-title":"Int J Mol Sci"},{"key":"4015_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175\u201391.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4015_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","volume":"51","author":"S Grosch","year":"2012","unstructured":"Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res. 2012;51:50\u201362.","journal-title":"Prog Lipid Res"},{"key":"4015_CR4","doi-asserted-by":"publisher","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965.","journal-title":"Front Neurosci"},{"key":"4015_CR5","first-page":"100344","volume":"19","author":"SJ Chin","year":"2022","unstructured":"Chin SJ, Fuller M. Prevalence of lysosomal storage disorders in Australia from 2009 to 2020. Lancet Reg Health West Pac. 2022;19:100344.","journal-title":"Lancet Reg Health West Pac"},{"key":"4015_CR6","unstructured":"Hughes DA, Pastores GM. Gaucher Disease. University of Washington, Seattle, Seattle (WA); Updated: 2023."},{"key":"4015_CR7","first-page":"10","volume":"5","author":"T Roshan Lal","year":"2017","unstructured":"Roshan Lal T, Sidransky E. The spectrum of neurological manifestations associated with gaucher disease. Dis. 2017;5:10.","journal-title":"Dis"},{"key":"4015_CR8","doi-asserted-by":"crossref","unstructured":"Donald A, Jones SA, Hughes DA, Church HJ, Cox TM, Consortium G. Gaucher disease type 3: classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort. Genet Med. 2025;27:101502.","DOI":"10.1016\/j.gim.2025.101502"},{"key":"4015_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2014.07.022","volume":"113","author":"A Sechi","year":"2014","unstructured":"Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 gaucher patients. Mol Genet Metab. 2014;113:213\u20138.","journal-title":"Mol Genet Metab"},{"key":"4015_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/EBC20190090","volume":"64","author":"M van Eijk","year":"2020","unstructured":"van Eijk M, Ferraz MJ, Boot RG, Aerts J. Lyso-glycosphingolipids: presence and consequences. Essays Biochem. 2020;64:565\u201378.","journal-title":"Essays Biochem"},{"key":"4015_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ymgme.2015.12.006","volume":"117","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques AR, Gaspar P, Mirzaian M, van Roomen C, Ottenhoff R, Alfonso P, Irun P, Giraldo P, Wisse P, Sa Miranda C, Overkleeft HS, Aerts JM. Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. Mol Genet Metab. 2016;117:186\u201393.","journal-title":"Mol Genet Metab"},{"key":"4015_CR12","doi-asserted-by":"publisher","first-page":"jcs221739","DOI":"10.1242\/jcs.221739","volume":"132","author":"AR Marques","year":"2019","unstructured":"Marques AR, Saftig P. Lysosomal storage disorders\u2013challenges, concepts and avenues for therapy: beyond rare diseases. J Cell Sci. 2019;132:jcs221739.","journal-title":"J Cell Sci"},{"key":"4015_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","volume":"14","author":"UH Schueler","year":"2003","unstructured":"Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, Brady RO. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in gaucher disease type 2 and 3. Neurobiol Dis. 2003;14:595\u2013601.","journal-title":"Neurobiol Dis"},{"key":"4015_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1046\/j.1471-4159.2003.01941.x","volume":"86","author":"E Haq","year":"2003","unstructured":"Haq E, Giri S, Singh I, Singh AK. Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. J Neurochem. 2003;86:1428\u201340.","journal-title":"J Neurochem"},{"key":"4015_CR15","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"4015_CR16","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"4015_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.prosdent.2022.05.019","volume":"131","author":"VH Sheth","year":"2024","unstructured":"Sheth VH, Shah NP, Jain R, Bhanushali N, Bhatnagar V. Development and validation of a risk-of-bias tool for assessing in vitro studies conducted in dentistry: the QUIN. J Prosthet Dent. 2024;131:1038\u201342.","journal-title":"J Prosthet Dent"},{"key":"4015_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"key":"4015_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02024331","volume":"149","author":"K Harzer","year":"1989","unstructured":"Harzer K, Paton BC, Poulos A, Kustermann-Kuhn B, Roggendorf W, Grisar T, Popp M. Sphingolipid activator protein deficiency in a 16-week-old atypical gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur J Pediatr. 1989;149:31\u20139.","journal-title":"Eur J Pediatr"},{"issue":"Suppl 2","key":"4015_CR20","first-page":"106","volume":"24","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24(Suppl 2):106\u201321. discussion 87\u2009\u2013\u20098.","journal-title":"J Inherit Metab Dis"},{"key":"4015_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","volume":"389","author":"K Ghauharali-van der Vlugt","year":"2008","unstructured":"Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, Groener JE. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I gaucher disease. Clin Chim Acta. 2008;389:109\u201313.","journal-title":"Clin Chim Acta"},{"key":"4015_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0022-2275(20)38985-9","volume":"6","author":"WD Suomi","year":"1965","unstructured":"Suomi WD, Agranoff BW. Lipids of the spleen in gaucher\u2019s disease. J Lipid Res. 1965;6:211\u20139.","journal-title":"J Lipid Res"},{"key":"4015_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","volume":"19","author":"Y Sun","year":"2010","unstructured":"Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA. Neuronopathic gaucher disease in the mouse: viable combined selective Saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010;19:1088\u201397.","journal-title":"Hum Mol Genet"},{"key":"4015_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nbd.2016.03.011","volume":"91","author":"L Karageorgos","year":"2016","unstructured":"Karageorgos L, Hein L, Rozaklis T, Adams M, Duplock S, Snel M, Hemsley K, Kuchel T, Smith N, Hopwood JJ. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic gaucher disease. Neurobiol Dis. 2016;91:143\u201354.","journal-title":"Neurobiol Dis"},{"key":"4015_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1399-0004.1985.tb00229.x","volume":"27","author":"O Nilsson","year":"1985","unstructured":"Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 gaucher disease variants. Clin Genet. 1985;27:443\u201350.","journal-title":"Clin Genet"},{"key":"4015_CR26","first-page":"523","volume":"80","author":"TT Kuske","year":"1972","unstructured":"Kuske TT, Rosenberg A. Quantity and fatty acyl composition of the glycosphingolipids of gaucher spleen. J Lab Clin Med. 1972;80:523\u20139.","journal-title":"J Lab Clin Med"},{"key":"4015_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile gaucher disease. J Neurochem. 1982;39:709\u201318.","journal-title":"J Neurochem"},{"key":"4015_CR28","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1194\/jlr.M800092-JLR200","volume":"49","author":"LK Hein","year":"2008","unstructured":"Hein LK, Duplock S, Hopwood JJ, Fuller M. Lipid composition of microdomains is altered in a cell model of gaucher disease. J Lipid Res. 2008;49:1725\u201334.","journal-title":"J Lipid Res"},{"key":"4015_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2013.11.009","volume":"442","author":"KJ Hattersley","year":"2013","unstructured":"Hattersley KJ, Hein LK, Fuller M. Lipid composition of membrane rafts, isolated with and without detergent, from the spleen of a mouse model of gaucher disease. Biochem Biophys Res Commun. 2013;442:62\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"4015_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ymgme.2007.08.001","volume":"92","author":"LK Hein","year":"2007","unstructured":"Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of gaucher disease. Mol Genet Metab. 2007;92:336\u201345.","journal-title":"Mol Genet Metab"},{"key":"4015_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00428-005-1246-y","volume":"447","author":"H Hulkova","year":"2005","unstructured":"Hulkova H, Ledvinova J, Asfaw B, Koubek K, Kopriva K, Elleder M. Lactosylceramide in lysosomal storage disorders: a comparative immunohistochemical and biochemical study. Virchows Arch. 2005;447:31\u201344.","journal-title":"Virchows Arch"},{"key":"4015_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1620\/tjem.88.277","volume":"88","author":"A Makita","year":"1966","unstructured":"Makita A, Suzuki C, Yosizawa Z, Konno T. Glycolipids isolated from the spleen of gaucher\u2019s disease. Tohoku J Exp Med. 1966;88:277\u201388.","journal-title":"Tohoku J Exp Med"},{"key":"4015_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2017.05.010","volume":"121","author":"LK Hein","year":"2017","unstructured":"Hein LK, Rozaklis T, Adams MK, Hopwood JJ, Karageorgos L. Lipid composition of microdomains is altered in neuronopathic gaucher disease sheep brain and spleen. Mol Genet Metab. 2017;121:259\u201370.","journal-title":"Mol Genet Metab"},{"key":"4015_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","volume":"122","author":"LA Boven","year":"2004","unstructured":"Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122:359\u201369.","journal-title":"Am J Clin Pathol"},{"key":"4015_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ymgme.2012.04.020","volume":"106","author":"MK Pandey","year":"2012","unstructured":"Pandey MK, Rani R, Zhang W, Setchell K, Grabowski GA. Immunological cell type characterization and Th1\u2013Th17 cytokine production in a mouse model of gaucher disease. Mol Genet Metab. 2012;106:310\u201322.","journal-title":"Mol Genet Metab"},{"key":"4015_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1203\/00006450-199601000-00020","volume":"39","author":"E Sidransky","year":"1996","unstructured":"Sidransky E, Fartasch M, Lee RE, Metlay LA, Abella S, Zimran A, Gao W, Elias PM, Ginns EI, Holleran WM. Epidermal abnormalities May distinguish type 2 from type 1 and type 3 of gaucher disease. Pediatr Res. 1996;39:134\u201341.","journal-title":"Pediatr Res"},{"key":"4015_CR37","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1074\/jbc.M116.762831","volume":"292","author":"S Schonauer","year":"2017","unstructured":"Schonauer S, Korschen HG, Penno A, Rennhack A, Breiden B, Sandhoff K, Gutbrod K, Dormann P, Raju DN, Haberkant P, Gerl MJ, Brugger B, Zigdon H, Vardi A, Futerman AH, Thiele C, Wachten D. Identification of a feedback loop involving beta-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in gaucher disease. J Biol Chem. 2017;292:6177\u201389.","journal-title":"J Biol Chem"},{"key":"4015_CR38","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1038\/s41598-019-41914-7","volume":"9","author":"B Liou","year":"2019","unstructured":"Liou B, Zhang W, Fannin V, Quinn B, Ran H, Xu K, Setchell KDR, Witte D, Grabowski GA, Sun Y. Combination of acid beta-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype. Sci Rep. 2019;9:5571.","journal-title":"Sci Rep"},{"key":"4015_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ymgme.2007.11.011","volume":"93","author":"M Fuller","year":"2008","unstructured":"Fuller M, Rozaklis T, Lovejoy M, Zarrinkalam K, Hopwood JJ, Meikle PJ. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with gaucher disease. Mol Genet Metab. 2008;93:437\u201343.","journal-title":"Mol Genet Metab"},{"key":"4015_CR40","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","volume":"19","author":"AM Vaccaro","year":"2010","unstructured":"Vaccaro AM, Motta M, Tatti M, Scarpa S, Masuelli L, Bhat M, Vanier MT, Tylki-Szymanska A, Salvioli R. Saposin C mutations in gaucher disease patients resulting in lysosomal lipid accumulation, Saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet. 2010;19:2987\u201397.","journal-title":"Hum Mol Genet"},{"key":"4015_CR41","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1093\/hmg\/ddv153","volume":"24","author":"M Tatti","year":"2015","unstructured":"Tatti M, Motta M, Scarpa S, Di Bartolomeo S, Cianfanelli V, Tartaglia M, Salvioli R. BCM-95 and (2-hydroxypropyl)-beta-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts. Hum Mol Genet. 2015;24:4198\u2013211.","journal-title":"Hum Mol Genet"},{"key":"4015_CR42","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1172\/JCI117160","volume":"93","author":"WM Holleran","year":"1994","unstructured":"Holleran WM, Ginns EI, Menon GK, Grundmann JU, Fartasch M, McKinney CE, Elias PM, Sidransky E. Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in gaucher disease. J Clin Invest. 1994;93:1756\u201364.","journal-title":"J Clin Invest"},{"key":"4015_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0014-5793(99)00274-4","volume":"447","author":"T Doering","year":"1999","unstructured":"Doering T, Proia RL, Sandhoff K. Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 gaucher mice. FEBS Lett. 1999;447:167\u201370.","journal-title":"FEBS Lett"},{"key":"4015_CR44","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","volume":"163","author":"YH Xu","year":"2003","unstructured":"Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in gaucher disease. Am J Pathol. 2003;163:2093\u2013101.","journal-title":"Am J Pathol"},{"key":"4015_CR45","first-page":"212","volume":"45","author":"B Theophilus","year":"1989","unstructured":"Theophilus B, Latham T, Grabowski GA, Smith FI. Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet. 1989;45:212\u201325.","journal-title":"Am J Hum Genet"},{"key":"4015_CR46","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1016\/S0021-9258(19)41492-0","volume":"250","author":"NW Barton","year":"1975","unstructured":"Barton NW, Rosenberg A. Metabolism of glucosyl [13H]ceramide by human skin fibroblasts from normal and glucosylceramidotic subjects. J Biol Chem. 1975;250:3966\u201371.","journal-title":"J Biol Chem"},{"key":"4015_CR47","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1016\/S0021-9258(19)44850-3","volume":"247","author":"G Dawson","year":"1972","unstructured":"Dawson G, Matalon R, Dorfman A. Glycosphingolipids in cultured human skin fibroblasts. II. Characterization and metabolism in fibroblasts from patients with inborn errors of glycosphingolipid and mucopolysaccharide metabolism. J Biol Chem. 1972;247:5951\u20138.","journal-title":"J Biol Chem"},{"key":"4015_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/molecules29020453","volume":"29","author":"C Ceni","year":"2024","unstructured":"Ceni C, Clemente F, Mangiavacchi F, Matassini C, Tonin R, Caciotti A, Feo F, Coviello D, Morrone A, Cardona F, Calamai M. Identification of GM1-Ganglioside secondary accumulation in fibroblasts from neuropathic gaucher patients and effect of a trivalent Trihydroxypiperidine Iminosugar compound on its storage reduction. Mol. 2024;29:453.","journal-title":"Mol"},{"key":"4015_CR49","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0021-9258(18)89553-9","volume":"260","author":"M Saito","year":"1985","unstructured":"Saito M, Rosenberg A. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) gaucher disease diploid human fibroblasts. J Biol Chem. 1985;260:2295\u2013300.","journal-title":"J Biol Chem"},{"key":"4015_CR50","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/hmg\/ddt468","volume":"23","author":"T Farfel-Becker","year":"2014","unstructured":"Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, Merrill AH Jr., Dobrenis K, Futerman AH. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic gaucher disease leads to neurodegeneration. Hum Mol Genet. 2014;23:843\u201354.","journal-title":"Hum Mol Genet"},{"key":"4015_CR51","doi-asserted-by":"publisher","first-page":"e179126","DOI":"10.1172\/jci.insight.179126","volume":"9","author":"HB Duffy","year":"2024","unstructured":"Duffy HB, Byrnes C, Zhu H, Tuymetova G, Lee YT, Platt FM, Proia RL. Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a gaucher mouse model. JCI Insight. 2024;9:e179126.","journal-title":"JCI Insight"},{"key":"4015_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352.","journal-title":"Cell"},{"key":"4015_CR53","doi-asserted-by":"publisher","first-page":"21673","DOI":"10.1074\/jbc.274.31.21673","volume":"274","author":"E Korkotian","year":"1999","unstructured":"Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH. Elevation of intracellular glucosylceramide levels results in an increase in Endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem. 1999;274:21673\u20138.","journal-title":"J Biol Chem"},{"key":"4015_CR54","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AH. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25:3432\u201345.","journal-title":"Hum Mol Genet"},{"key":"4015_CR55","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/cells11152343","volume":"11","author":"G Lunghi","year":"2022","unstructured":"Lunghi G, Carsana EV, Loberto N, Cioccarelli L, Prioni S, Mauri L, Bassi R, Duga S, Straniero L, Asselta R, Solda G, Di Fonzo A, Frattini E, Magni M, Liessi N, Armirotti A, Ferrari E, Samarani M, Aureli M. beta-Glucocerebrosidase deficiency activates an aberrant Lysosome-Plasma membrane axis responsible for the onset of neurodegeneration. Cell. 2022;11:2343.","journal-title":"Cell"},{"key":"4015_CR56","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1080\/15548627.2015.1086055","volume":"11","author":"TT Du","year":"2015","unstructured":"Du TT, Wang L, Duan CL, Lu LL, Zhang JL, Gao G, Qiu XB, Wang XM, Yang H. GBA deficiency promotes SNCA\/alpha-synuclein accumulation through autophagic Inhibition by inactivated PPP2A. Autophagy. 2015;11:1803\u201320.","journal-title":"Autophagy"},{"key":"4015_CR57","doi-asserted-by":"crossref","unstructured":"Sudo M. Brain glycolipids in infantile Gaucher's disease. J Neurochem. 1977;29:379\u201381.","DOI":"10.1111\/j.1471-4159.1977.tb09636.x"},{"key":"4015_CR58","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1471-4159.1979.tb04582.x","volume":"32","author":"MC Stephens","year":"1979","unstructured":"Stephens MC, Bernatsky A, Legler G, Kanfer JN. The gaucher mouse: additional biochemical alterations. J Neurochem. 1979;32:969\u201372.","journal-title":"J Neurochem"},{"key":"4015_CR59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/path.4992","volume":"244","author":"NJ Smith","year":"2018","unstructured":"Smith NJ, Fuller M, Saville JT, Cox TM. Reduced cerebral vascularization in experimental neuronopathic gaucher disease. J Pathol. 2018;244:120\u20138.","journal-title":"J Pathol"},{"key":"4015_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.24.2.162","volume":"24","author":"F Gonzalez-Sastre","year":"1974","unstructured":"Gonzalez-Sastre F, Pampols T, Sabater J. Infantile gaucher\u2019s disease: A biochemical study. Neurol. 1974;24:162\u20137.","journal-title":"Neurol"},{"key":"4015_CR61","first-page":"513","volume":"42","author":"M Kubota","year":"1972","unstructured":"Kubota M. Studies on neural and visceral glycolipids in a case of infantile form of gaucher\u2019s disease. Jpn J Exp Med. 1972;42:513\u201326.","journal-title":"Jpn J Exp Med"},{"key":"4015_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s004010050960","volume":"97","author":"T Pampols","year":"1999","unstructured":"Pampols T, Pineda M, Giros ML, Ferrer I, Cusi V, Chabas A, Sanmarti FX, Vanier MT, Christomanou H. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this gaucher disease variant. Acta Neuropathol. 1999;97:91\u20137.","journal-title":"Acta Neuropathol"},{"key":"4015_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13024-024-00713-z","volume":"19","author":"I Gregorio","year":"2024","unstructured":"Gregorio I, Russo L, Torretta E, Barbacini P, Contarini G, Pacinelli G, Bizzotto D, Moriggi M, Braghetta P, Papaleo F, Gelfi C, Moro E, Cescon M. GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice. Mol Neurodegener. 2024;19:22.","journal-title":"Mol Neurodegener"},{"key":"4015_CR64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1006\/mgme.2001.3269","volume":"75","author":"PD Whitfield","year":"2002","unstructured":"Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, Fong BA, Fietz MJ, Hopwood JJ, Meikle PJ. Correlation among genotype, phenotype, and biochemical markers in gaucher disease: implications for the prediction of disease severity. Mol Genet Metab. 2002;75:46\u201355.","journal-title":"Mol Genet Metab"},{"key":"4015_CR65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.bcmd.2007.10.004","volume":"40","author":"PJ Meikle","year":"2008","unstructured":"Meikle PJ, Whitfield PD, Rozaklis T, Blacklock D, Duplock S, Elstein D, Zimran A, Mengel E, Cannell P, Hopwood JJ, Fuller M. Plasma lipids are altered in gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cell Mol Dis. 2008;40:420\u20137.","journal-title":"Blood Cell Mol Dis"},{"key":"4015_CR66","doi-asserted-by":"publisher","first-page":"10177","DOI":"10.3390\/ijms241210177","volume":"24","author":"J Spiewak","year":"2023","unstructured":"Spiewak J, Doykov I, Papandreou A, Hallqvist J, Mills P, Clayton PT, Gissen P, Mills K, Heywood WE. New perspectives in dried blood spot biomarkers for lysosomal storage diseases. Int J Mol Sci. 2023;24:10177.","journal-title":"Int J Mol Sci"},{"key":"4015_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0022-2275(20)42667-7","volume":"10","author":"DE Vance","year":"1969","unstructured":"Vance DE, Krivit W, Sweeley CC. Concentrations of Glycosyl ceramides in plasma and red cells in fabry\u2019s disease, a glycolipid lipidosis. J Lipid Res. 1969;10:188\u201392.","journal-title":"J Lipid Res"},{"key":"4015_CR68","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.1400768111","volume":"111","author":"PK Mistry","year":"2014","unstructured":"Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Stachnik A, Mennone A, Boyer JL, Jain D, Brady RO, New MI, Zaidi M. Glucocerebrosidase 2 gene deletion rescues type 1 gaucher disease. Proc Natl Acad Sci U S A. 2014;111:4934\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4015_CR69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","volume":"1781","author":"JE Groener","year":"2008","unstructured":"Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM. Plasma glucosylceramide and ceramide in type 1 gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta. 2008;1781:72\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"4015_CR70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.chroma.2015.01.004","volume":"1381","author":"SK Byeon","year":"2015","unstructured":"Byeon SK, Lee JY, Lee JS, Moon MH. Lipidomic profiling of plasma and urine from patients with gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2015;1381:132\u20139.","journal-title":"J Chromatogr A"},{"key":"4015_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1015137917508","volume":"25","author":"R Gornati","year":"2002","unstructured":"Gornati R, Berra B, Montorfano G, Martini C, Ciana G, Ferrari P, Romano M, Bembi B. Glycolipid analysis of different tissues and cerebrospinal fluid in type II gaucher disease. J Inherit Metab Dis. 2002;25:47\u201355.","journal-title":"J Inherit Metab Dis"},{"key":"4015_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/brain\/awac379","volume":"146","author":"R Schiffmann","year":"2023","unstructured":"Schiffmann R, Cox TM, Dedieu JF, Gaemers SJM, Hennermann JB, Ida H, Mengel E, Minini P, Mistry P, Musholt PB, Scott D, Sharma J, Peterschmitt MJ. Venglustat combined with imiglucerase for neurological disease in adults with gaucher disease type 3: the LEAP trial. Brain. 2023;146:461\u201374.","journal-title":"Brain"},{"key":"4015_CR73","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4452","volume":"235","author":"EV Pavlova","year":"2015","unstructured":"Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, Cox TM. Inhibition of UDP-glucosylceramide synthase in mice prevents gaucher disease-associated B-cell malignancy. J Pathol. 2015;235:113\u201324.","journal-title":"J Pathol"},{"key":"4015_CR74","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bcmd.2014.01.005","volume":"53","author":"M Moraitou","year":"2014","unstructured":"Moraitou M, Dimitriou E, Dekker N, Monopolis I, Aerts J, Michelakakis H. Gaucher disease: plasmalogen levels in relation to primary lipid abnormalities and oxidative stress. Blood Cell Mol Dis. 2014;53:30\u20133.","journal-title":"Blood Cell Mol Dis"},{"key":"4015_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0009-8981(76)90045-0","volume":"72","author":"C Klibansky","year":"1976","unstructured":"Klibansky C, Ossimi Z, Matoth Y, Pinkhas J, de Vries A. Accumulation of lactosyl ceramide in leukocytes of patients with adult gaucher\u2019s disease. Clin Chim Acta. 1976;72:141\u20136.","journal-title":"Clin Chim Acta"},{"key":"4015_CR76","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","volume":"27","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Jeon S, Burbulla LF, Krainc D. Acid ceramidase Inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet. 2018;27:1972\u201388.","journal-title":"Hum Mol Genet"},{"key":"4015_CR77","doi-asserted-by":"publisher","first-page":"e116023","DOI":"10.1371\/journal.pone.0116023","volume":"9","author":"S Barnes","year":"2014","unstructured":"Barnes S, Xu YH, Zhang W, Liou B, Setchell KD, Bao L, Grabowski GA, Sun Y. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a gaucher disease mouse model. PLoS ONE. 2014;9:e116023.","journal-title":"PLoS ONE"},{"key":"4015_CR78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","volume":"18","author":"G Giuffrida","year":"2023","unstructured":"Giuffrida G, Markovic U, Condorelli A, Calafiore V, Nicolosi D, Calagna M, Grasso S, Ragusa MTV, Gentile J, Napolitano M. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in gaucher disease: a narrative review. Orphanet J Rare Dis. 2023;18:27.","journal-title":"Orphanet J Rare Dis"},{"key":"4015_CR79","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1194\/jlr.D800051-JLR200","volume":"50","author":"RL Shaner","year":"2009","unstructured":"Shaner RL, Allegood JC, Park H, Wang E, Kelly S, Haynes CA, Sullards MC, Merrill AH. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers [S]. J Lipid Res. 2009;50:1692\u2013707.","journal-title":"J Lipid Res"},{"key":"4015_CR80","doi-asserted-by":"publisher","first-page":"109139","DOI":"10.1016\/j.ymgme.2025.109139","volume":"145","author":"A Lake","year":"2025","unstructured":"Lake A, Saville J, Fuller M. Sphingolipid de Novo synthesis is upregulated in a macrophage model of gaucher disease. Mol Genet Metab. 2025;145:109139.","journal-title":"Mol Genet Metab"},{"key":"4015_CR81","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1194\/jlr.S092874","volume":"60","author":"JL Stith","year":"2019","unstructured":"Stith JL, Velazquez FN, Obeid LM. Advances in determining signaling mechanisms of ceramide and role in disease. J Lipid Res. 2019;60:913\u20138.","journal-title":"J Lipid Res"},{"key":"4015_CR82","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1074\/jbc.M112.419978","volume":"288","author":"JD Schilling","year":"2013","unstructured":"Schilling JD, Machkovech HM, He L, Sidhu R, Fujiwara H, Weber K, Ory DS, Schaffer JE. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J Biol Chem. 2013;288:2923\u201332.","journal-title":"J Biol Chem"},{"key":"4015_CR83","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1210\/er.2007-0025","volume":"29","author":"WL Holland","year":"2008","unstructured":"Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocrin Rev. 2008;29:381\u2013402.","journal-title":"Endocrin Rev"},{"key":"4015_CR84","doi-asserted-by":"publisher","first-page":"29402","DOI":"10.1074\/jbc.M115.680199","volume":"290","author":"CD Camell","year":"2015","unstructured":"Camell CD, Nguyen KY, Jurczak MJ, Christian BE, Shulman GI, Shadel GS, Dixit VD. Macrophage-specific de Novo synthesis of ceramide is dispensable for inflammasome-driven inflammation and insulin resistance in obesity. J Biol Chem. 2015;290:29402\u201313.","journal-title":"J Biol Chem"},{"key":"4015_CR85","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.cmet.2014.08.002","volume":"20","author":"SM Turpin","year":"2014","unstructured":"Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Br\u00f6nneke HS. Obesity-induced CerS6-dependent C16: 0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014;20:678\u201386.","journal-title":"Cell Metab"},{"key":"4015_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0925-4439(96)00056-7","volume":"1317","author":"H Michelakakis","year":"1996","unstructured":"Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor necrosis factor-a (TNF-a) levels in gaucher disease. Biochim Biophys Acta Mol Basis Dis. 1996;1317:219\u201322.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4015_CR87","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in gaucher\u2019s disease. Euro Cytokine Netw. 1999;10:205\u201310.","journal-title":"Euro Cytokine Netw"},{"key":"4015_CR88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"M Allen","year":"1997","unstructured":"Allen M, Myer B, Khokher A, Rushton N, Cox T. Pro-inflammatory cytokines and the pathogenesis of gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM: Int J Med. 1997;90:19\u201325.","journal-title":"QJM: Int J Med"},{"key":"4015_CR89","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejmhg.2015.02.001","volume":"16","author":"AA Tantawy","year":"2015","unstructured":"Tantawy AA. Cytokines in gaucher disease: role in the pathogenesis of bone and pulmonary disease. Egypt J Med Hum Genet. 2015;16:207\u201313.","journal-title":"Egypt J Med Hum Genet"},{"key":"4015_CR90","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1038\/cddis.2012.17","volume":"3","author":"E Aflaki","year":"2012","unstructured":"Aflaki E, Doddapattar P, Radovi\u0107 B, Povoden S, Kolb D, Vuji\u0107 N, Wegscheider M, Koefeler H, Hornemann T, Graier W. C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages. Cell Death Dis. 2012;3:e280\u2013e.","journal-title":"Cell Death Dis"},{"key":"4015_CR91","doi-asserted-by":"publisher","first-page":"9697","DOI":"10.3390\/ijms23179697","volume":"23","author":"QWC Ho","year":"2022","unstructured":"Ho QWC, Zheng X, Ali Y. Ceramide acyl chain length and its relevance to intracellular lipid regulation. Int J Mol Sci. 2022;23:9697.","journal-title":"Int J Mol Sci"},{"key":"4015_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.advms.2023.10.004","volume":"68","author":"MB Pil\u00e1tov\u00e1","year":"2023","unstructured":"Pil\u00e1tov\u00e1 MB, Sol\u00e1rov\u00e1 Z, Mezencev R, Sol\u00e1r P. Ceramides and their roles in programmed cell death. Adv Med Sci. 2023;68:417\u201325.","journal-title":"Adv Med Sci"},{"key":"4015_CR93","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1016\/j.jaip.2020.06.065","volume":"8","author":"M Miano","year":"2020","unstructured":"Miano M, Madeo A, Cappelli E, Lanza F, Lanza T, Stroppiano M, Terranova P, Ven\u00e8 R, Bleesing JJ, Di Rocco M. Defective FAS-Mediated apoptosis and immune dysregulation in gaucher disease. J Allergy Clin Immunol Prac. 2020;8:3535\u201342.","journal-title":"J Allergy Clin Immunol Prac"},{"key":"4015_CR94","doi-asserted-by":"publisher","first-page":"104679","DOI":"10.1016\/j.yexmp.2021.104679","volume":"123","author":"\u0141 Pawli\u0144ski","year":"2021","unstructured":"Pawli\u0144ski \u0141, Polus A, Ka\u0142u\u017cna M, Sordyl M, Tob\u00f3r-\u015awi\u0119tek E, Krawczyk M, Bednarek M, Solnica B, Rucha\u0142a M. Kie\u0107-Wilk B. Gene expression with corresponding pathways analysis in gaucher disease. Exp Mol Pathol. 2021;123:104679.","journal-title":"Exp Mol Pathol"},{"key":"4015_CR95","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tem.2017.03.005","volume":"28","author":"J Iqbal","year":"2017","unstructured":"Iqbal J, Walsh MT, Hammad SM, Hussain MM. Sphingolipids and lipoproteins in health and metabolic disorders. Trends Endocrin Metab. 2017;28:506\u201318.","journal-title":"Trends Endocrin Metab"},{"key":"4015_CR96","doi-asserted-by":"crossref","unstructured":"Chakraborty M, Jiang X-C. Sphingomyelin and its role in cellular signaling. Lipid Med Protein Signal. 2013;991:1\u201314.","DOI":"10.1007\/978-94-007-6331-9_1"},{"key":"4015_CR97","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, Schiffmann R. Neuropathology provides clues to the pathophysiology of gaucher disease. Mol Genet Metab. 2004;82:192\u2013207.","journal-title":"Mol Genet Metab"},{"key":"4015_CR98","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12974-016-0570-2","volume":"13","author":"EB Vitner","year":"2016","unstructured":"Vitner EB, Farfel-Becker T, Ferreira NS, Leshkowitz D, Sharma P, Lang KS, Futerman AH. Induction of the type I interferon response in neurological forms of gaucher disease. J Neuroinflammation. 2016;13:104.","journal-title":"J Neuroinflammation"},{"key":"4015_CR99","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms23105842","volume":"23","author":"ML Furderer","year":"2022","unstructured":"Furderer ML, Hertz E, Lopez GJ, Sidransky E. Neuropathological features of gaucher disease and gaucher disease with parkinsonism. Int J Mol Sci. 2022;23:5842.","journal-title":"Int J Mol Sci"},{"key":"4015_CR100","doi-asserted-by":"publisher","first-page":"13742","DOI":"10.1074\/jbc.M411959200","volume":"280","author":"R Pannu","year":"2005","unstructured":"Pannu R, Singh AK, Singh I. A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes. Implications for astrogliosis following neurotrauma. J Biol Chem. 2005;280:13742\u201351.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"4015_CR101","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1471-4159.2007.04822.x","volume":"103","author":"JS Won","year":"2007","unstructured":"Won JS, Singh AK, Singh I. Lactosylceramide: a lipid second messenger in neuroinflammatory disease. J Neurochem. 2007;103(Suppl 1):180\u201391.","journal-title":"J Neurochem"},{"key":"4015_CR102","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/ijms22041816","volume":"22","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Balram A, Li W. Convergence: lactosylceramide-centric signaling pathways induce inflammation, oxidative stress, and other phenotypic outcomes. Int J Mol Sci. 2021;22:1816.","journal-title":"Int J Mol Sci"},{"key":"4015_CR103","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.3390\/ijms23147640","volume":"23","author":"L Dupuis","year":"2022","unstructured":"Dupuis L, Chauvet M, Bourdelier E, Dussiot M, Belmatoug N, Le Van Kim C, Chene A, Franco M. Phagocytosis of erythrocytes from gaucher patients induces phenotypic modifications in macrophages, driving them toward gaucher cells. Int J Mol Sci. 2022;23:7640.","journal-title":"Int J Mol Sci"},{"key":"4015_CR104","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41594-021-00562-0","volume":"28","author":"BW Wattenberg","year":"2021","unstructured":"Wattenberg BW. Kicking off sphingolipid biosynthesis: structures of the Serine palmitoyltransferase complex. Nat Struct Mol Biol. 2021;28:229\u201331.","journal-title":"Nat Struct Mol Biol"},{"key":"4015_CR105","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/1673-5374.343890","volume":"18","author":"JF Vasques","year":"2023","unstructured":"Vasques JF, de Jesus Goncalves RG, da Silva-Junior AJ, Martins RS, Gubert F, Mendez-Otero R. Gangliosides in nervous system development, regeneration, and pathologies. Neural Regen Res. 2023;18:81\u20136.","journal-title":"Neural Regen Res"},{"key":"4015_CR106","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/emm.2006.79","volume":"38","author":"D-H Kwak","year":"2006","unstructured":"Kwak D-H, Yu K, Kim S-M, Lee D-H, Kim S-M, Jung J-U, Seo J-W, Kim N, Lee S, Jung K-Y. Dynamic changes of gangliosides expression during the differentiation of embryonic and mesenchymal stem cells into neural cells. Exp Mol Med. 2006;38:668\u201376.","journal-title":"Exp Mol Med"},{"key":"4015_CR107","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/nu7053891","volume":"7","author":"K Palmano","year":"2015","unstructured":"Palmano K, Rowan A, Guillermo R, Guan J, Mc Jarrow P. The role of gangliosides in neurodevelopment. Nutrients. 2015;7:3891\u2013913.","journal-title":"Nutrients"},{"key":"4015_CR108","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/0005-2760(73)90185-9","volume":"306","author":"G Tettamanti","year":"1973","unstructured":"Tettamanti G, Preti A, Lombardo A, Bonali F, Zambotti V. Parallelism of subcellular location of major particulate neuraminidase and gangliosides in rabbit brain cortex. Biochim Biophys Acta. 1973;306:466\u201377.","journal-title":"Biochim Biophys Acta"},{"key":"4015_CR109","doi-asserted-by":"crossref","unstructured":"Ledeen R, Chowdhury S. Gangliosides in neurodegenerative diseases. Glycobiology of the nervous system. Springer; 2022. pp. 391\u2013418.","DOI":"10.1007\/978-3-031-12390-0_13"},{"key":"4015_CR110","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/hmg\/ddz184","volume":"28","author":"Y Peng","year":"2019","unstructured":"Peng Y, Liou B, Inskeep V, Blackwood R, Mayhew CN, Grabowski GA, Sun Y. Intravenous infusion of iPSC-derived neural precursor cells increases acid beta-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of gaucher disease. Hum Mol Genet. 2019;28:3406\u201321.","journal-title":"Hum Mol Genet"},{"key":"4015_CR111","doi-asserted-by":"crossref","unstructured":"Awad O, Panicker LM, Deranieh RM, Srikanth MP, Brown RA, Voit A, Peesay T, Park TS, Zambidis ET, Feldman RA. Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt\/beta-Catenin Downregulation. Stem Cell Rep. 2017;9:1853\u201367","DOI":"10.1016\/j.stemcr.2017.10.029"},{"key":"4015_CR112","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1523\/JNEUROSCI.4432-13.2014","volume":"34","author":"S Kappagantula","year":"2014","unstructured":"Kappagantula S, Andrews MR, Cheah M, Abad-Rodriguez J, Dotti CG, Fawcett JW. Neu3 sialidase-mediated ganglioside conversion is necessary for axon regeneration and is blocked in CNS axons. J Neurosci. 2014;34:2477\u201392.","journal-title":"J Neurosci"},{"key":"4015_CR113","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","volume":"20","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH. Spatial and Temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic gaucher disease. Hum Mol Genet. 2011;20:1375\u201386.","journal-title":"Hum Mol Genet"},{"key":"4015_CR114","doi-asserted-by":"publisher","first-page":"17483","DOI":"10.1073\/pnas.0708086104","volume":"104","author":"IB Enquist","year":"2007","unstructured":"Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S. Murine models of acute neuronopathic gaucher disease. Proc Natl Acad Sci U S A. 2007;104:17483\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4015_CR115","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","volume":"111","author":"EI Ginns","year":"2014","unstructured":"Ginns EI, Mak SK-K, Ko N, Karlgren J, Akbarian S, Chou VP, Guo Y, Lim A, Samuelsson S, LaMarca ML. Neuroinflammation and \u03b1-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol Genet Metab. 2014;111:152\u201362.","journal-title":"Mol Genet Metab"},{"key":"4015_CR116","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1074\/jbc.270.7.3074","volume":"270","author":"G Ferrari","year":"1995","unstructured":"Ferrari G, Anderson BL, Stephens RM, Kaplan DR, Greene LA. Prevention of apoptotic neuronal death by GM1 ganglioside: INVOLVEMENT OF Trk NEUROTROPHIN RECEPTORS (\u2217). J Biol Chem. 1995;270:3074\u201380.","journal-title":"J Biol Chem"},{"key":"4015_CR117","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1213\/ANE.0000000000004570","volume":"130","author":"C Meng","year":"2020","unstructured":"Meng C, Yao XQ, Chang RJ, Wang SL, Wang X, Ma DQ, Li Q, Wang XY. Exogenous GM1 ganglioside attenuates Ketamine-Induced neurocognitive impairment in the developing rat brain. Anesth Analg. 2020;130:505\u201317.","journal-title":"Anesth Analg"},{"key":"4015_CR118","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1016\/j.ymthe.2021.06.005","volume":"29","author":"Y Itokazu","year":"2021","unstructured":"Itokazu Y, Fuchigami T, Morgan JC, Yu RK. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse. Mol Ther. 2021;29:3059\u201371.","journal-title":"Mol Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04015-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:09:34Z","timestamp":1762423774000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04015-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04015-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"565"}}